Mesoblast (NASDAQ:MESO) Shares Gap Down – What’s Next?

Mesoblast Limited (NASDAQ:MESO)’s stock price gapped down before the market opened on Friday . The stock had previously closed at $16.92, but opened at $15.80. Mesoblast shares last traded at $15.87, with a volume of 179,801 shares.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Mesoblast in a research note on Thursday, January 22nd. Two research analysts have rated the stock with a Strong Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy”.

Mesoblast Stock Down 6.3%

The firm has a market cap of $2.05 billion, a price-to-earnings ratio of -18.01 and a beta of 2.15. The firm’s 50 day moving average price is $17.86 and its two-hundred day moving average price is $16.90. The company has a debt-to-equity ratio of 0.11, a current ratio of 1.99 and a quick ratio of 1.77.

Mesoblast (NASDAQ:MESO) last issued its quarterly earnings results on Thursday, January 29th. The company reported ($0.16) earnings per share (EPS) for the quarter. The company had revenue of $25.67 million during the quarter. As a group, sell-side analysts forecast that Mesoblast Limited will post -0.7 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Mesoblast

Several institutional investors have recently bought and sold shares of MESO. Quadrature Capital Ltd acquired a new stake in shares of Mesoblast in the 4th quarter worth $479,000. AQR Capital Management LLC raised its holdings in Mesoblast by 80.5% during the fourth quarter. AQR Capital Management LLC now owns 25,215 shares of the company’s stock worth $455,000 after purchasing an additional 11,242 shares in the last quarter. &PARTNERS acquired a new stake in Mesoblast in the fourth quarter valued at about $334,000. Opal Capital LLC purchased a new stake in Mesoblast in the 4th quarter valued at approximately $307,000. Finally, Tobias Financial Advisors Inc. boosted its holdings in Mesoblast by 38.3% in the 4th quarter. Tobias Financial Advisors Inc. now owns 13,828 shares of the company’s stock valued at $249,000 after purchasing an additional 3,828 shares in the last quarter. 1.43% of the stock is owned by institutional investors and hedge funds.

About Mesoblast

Mesoblast Limited is a global leader in allogeneic cellular medicines, focused on developing treatments for inflammatory and immunologic diseases. Founded in 2004 by Dr. Silviu Itescu, the company builds on proprietary mesenchymal lineage cell technology to create off-the-shelf, donor-derived therapies. These therapies are designed to modulate immune responses and promote tissue repair in conditions where existing medical options are limited or ineffective.

The company’s most advanced product, Alofisel® (darvadstrocel), has been approved in Europe for the treatment of complex perianal fistulas in adults with Crohn’s disease.